Overall rank by patents
#49,573
of 49,997 tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 9 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).
The verdict
According to USPTO PatentsView, Pharosgen ranks #49,573 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 9 technology areas.
USPTO PatentsView assignee plate
Corpus R49573 · Foreign Corporation #49,573 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
Nearest grant-volume peer: Phagelux (CANADA) Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
ABB AB · near
34 score
Fabbrica D'armi… · near
34 score
Kulicke & Soffa… · near
34 score
Pharosgen · this assignee
34 score
Trinity North… · near
34 score
3D Lighting… · lowest
7 score
What this shows Pharosgen's Innovation Score is 34.0/100 (46th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Pharosgen Co., Ltd is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2017. By volume, Pharosgen sits between Phagelux (CANADA) Inc. and Phosphorex, Inc..
Pharosgen Co., Ltd shows 1 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Phagelux (CANADA) Inc.
5 patents
Pharma Integration S.R.L.
5 patents
Pharmanutra S.P.A.
5 patents
Pharmaresearch Co., Ltd.
5 patents
Philoptics Co., Ltd.
5 patents
Philtech Inc.
5 patents
Phoenix II A/S
5 patents
Phosphorex, Inc.
5 patents
Pharosgen Co., Ltd
5 patents
What this shows Pharosgen holds 5 patents at rank #49,505, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #49,505 in granted patent volume.
Other assignees with the most granted patents in Pharosgen's primary technology class.
Two PlainPatent-derived peer sets for Pharosgen, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (34 here).
Pharosgen's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
34 46th percentile higher than 46% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 20.0% |
| 2019 | 3 | 60.0% |
| 2024 | 1 | 20.0% |
Top 9 of 9 technology areas
Overall rank by patents
#49,573
of 49,997 tracked assignees
34.0 out of 100
What to do with this data
Pharosgen Co., Ltd's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.